344 related articles for article (PubMed ID: 31588087)
1. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
[TBL] [Abstract][Full Text] [Related]
2. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
[TBL] [Abstract][Full Text] [Related]
3. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P
Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553
[No Abstract] [Full Text] [Related]
5. [Problems of diagnostics and treatment of transtiretinum amyloidosis with destruction of the heart in the elderly: Clinical experience.].
Boldueva SA; Petrova VB; Khavinson VK; Samohvalova MV; Petrova AI
Adv Gerontol; 2019; 32(1-2):137-144. PubMed ID: 31228380
[TBL] [Abstract][Full Text] [Related]
6. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
[TBL] [Abstract][Full Text] [Related]
8. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
Rubin J; Steidley DE; Carlsson M; Ong ML; Maurer MS
J Card Fail; 2018 Aug; 24(8):504-511. PubMed ID: 30010028
[TBL] [Abstract][Full Text] [Related]
9. [Transthyretin amyloidosis in a cohort of old and very old patients with chronic heart failure].
Poliakova AA; Semernin EN; Sitnikova MY; Аvagyan KL; Grozov RV; Pyko SA; Krutikov AN; Davydova VG; Khmelnitskaya KA; Shavloskii MM; Korzhevskii DE; Gudkova AY
Kardiologiia; 2018 SFeb; (S2):12-18. PubMed ID: 29782249
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
Kato K
Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
[TBL] [Abstract][Full Text] [Related]
13. Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure.
Kawano H; Arakawa S; Satoh O; Matsumoto Y; Hayano M; Nakatomi D; Yamasa T; Maemura K
Geriatr Gerontol Int; 2014 Jan; 14(1):109-14. PubMed ID: 23581555
[TBL] [Abstract][Full Text] [Related]
14. Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome.
Dowd RS; Nail TJ; Arkun K; Kryzanski J; Soto O; Fogaren T; Harrington K; Patel A; Comenzo R; Riesenburger RI
World Neurosurg; 2019 Nov; 131():104-107. PubMed ID: 31369882
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis.
Puig-Carrion GD; Reyentovich A; Katz SD
Clin Auton Res; 2019 Sep; 29(Suppl 1):45-53. PubMed ID: 31452023
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin amyloidosis: Putting myopathy on the map.
Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
19. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
[TBL] [Abstract][Full Text] [Related]
20. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Elliott P; Gundapaneni B; Sultan MB; Ines M; Garcia-Pavia P
Eur J Heart Fail; 2023 Nov; 25(11):2060-2064. PubMed ID: 37434378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
